AMRX News and Press, Amneal Pharmaceuticals Inc. Class A From 03/02/23

‒ Q4 2022 Net Revenue of $610 million; GAAP Net Loss of $4 million; Diluted Loss per Share of $0.03 ‒ ‒ Q4 2022 Adjusted Net Income of $71 million (1) , Adjusted EBITDA (1) of $154 million; Adjusted Diluted EPS (1) of $0.23 ‒ ‒ Full Y...

Amneal Pharmaceuticals ( NYSE: AMRX ) is scheduled to announce Q4 earnings results on Thursday, March 2nd, before market open. The consensus EPS Estimate is $0.21 (+16.7% Y/Y) and the consensus Revenue Estimate is $579.93M (+8.0% Y/Y). Over the last 2 years, AMRX has beaten ...

Summary Viatris' gross margin reached its highest level since its inception in the fourth quarter of 2020, despite rising raw material and labor costs. On February 27, 2023, Viatris management will publish financial results for the 4th quarter of 2022. Viatris' operating income for ...

If you’re looking for penny stocks to buy, you’re not alone. One of the main attractions to this niche in the stock market today is the potential for quick gains. Not only that, but in many cases, these gains can be extreme. On an almost daily basis, you’re sure to see at lea...

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2022 financial results on Thursday March 2, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. East...

Summary As a leader in various therapeutic areas, the company's total revenue was $7,042 million in the third quarter of 2022, up 12.5% quarter-on-quarter. Gilead will be required to make royalties of 3% on future sales of Biktarvy and bictegravir-containing medicines up to the 4th quar...

Summary The inability to efficiently market new drugs might put significant pressure on AMRX's margins, which can lead to a substantial stock price correction. As the business has been expanding its drug portfolio, in the upcoming years, profitability might improve significantly. I ...

The following slide deck was published by Amneal Pharmaceuticals, Inc. in conjunction with this event. For further details see: Amneal Pharmaceuticals (AMRX) presents at 41st Annual J.P. Morgan Healthcare Conference - Slideshow

Generic and specialty drugmaker Amneal Pharmaceuticals ( NYSE: AMRX ) reiterated its previously issued financial guidance for the year ending December 31, 2022, on Tuesday as part of its presentation at the ongoing JPMorgan Healthcare Conference. The detailed outlook indicates $2.15B ...

Amneal Pharmaceuticals ( NYSE: AMRX ) has signed a long-term license agreement with Orion Corporation to commercialize a number of complex generic products. Under the partnership agreement, Orion is Amneal’s exclusive partner to bring its portfolio of complex generic progra...